Daniel Curran

Daniel J.
Curran is Chief Executive Officer at Timberlyne Therapeutics, Inc. since 2025.
He is an Independent Director at Xilio Therapeutics, Inc. since 2020.
He serves as Director at Stargazer Pharmaceuticals, Inc. since 2019.
He is an Independent Director at ALX Oncology Holdings, Inc. since 2025.
He is Managing Partner at Mountainfield Venture Partners LLC since 2024.
Formerly, Dr. Curran was Director at Tome Biosciences, Inc. in 2024.
He was Director at Oak Hill Bio Corp.
from 2022 to 2024.
He was Director at Catalyst Pharmaceuticals, Inc. from 2025 to 2026.
He was Principal at DuPont Merck Pharmaceutical Co. He was Vice President-Business & Corporate Development at Millennium Pharmaceuticals, Inc. from 1999 to 2008.
He was Senior VP, Head-Rare Genetics & Hematology at Takeda Pharmaceutical Co., Ltd. from 2019 to 2023.
Dr. Curran completed undergraduate studies at King's College (Pennsylvania).
He earned an MBA from The Wharton School of the University of Pennsylvania.
He obtained a doctorate from the University of Pennsylvania Medical Center.